Background: Oligometastatic lung cancer is a clinical entity characterized by a limited number of metastases, and stereotactic body radiation therapy (SBRT) has emerged as a promising treatment option for this condition. However, the relationship between SBRT dose and adverse events in this population is not well understood.



Objectives: To evaluate the treatment outcomes and adverse events associated with SBRT in patients with oligometastatic lung cancer, and to investigate the relationship between radiation dose and adverse events.



Methods: This retrospective chart review included 81 patients with oligometastatic lung cancer who underwent SBRT at a single institution between 2015 and 2023. Patients received SBRT with a dose of 30-60 Gy in 3-10 fractions. Data on patient demographics, tumor characteristics, treatment details, and adverse events were collected and analyzed.



Results: The study found that 37% of patients experienced adverse events of grade ≥2, with fatigue, dermatitis, and cough being the most common. Multivariate analysis revealed that higher radiation dose was significantly associated with increased risk of adverse events (OR 1.05, 95% CI 1.01-1.09, p=0.01). Other factors, including age, sex, ECOG performance status, and previous chemotherapy, were not significantly associated with adverse events.



Conclusion: This study demonstrates that SBRT higher radiation doses are associated with increased risk of adverse events with no other risk factor predicting adverse event occurrence. These findings highlight the importance of careful treatment planning and dose optimization to minimize toxicity while maintaining treatment efficacy.